MARKET

SLN

SLN

Silence Therapeutics Plc
NASDAQ
19.80
+0.03
+0.15%
After Hours: 19.80 0 0.00% 16:15 11/12 EST
OPEN
19.76
PREV CLOSE
19.77
HIGH
19.82
LOW
19.76
VOLUME
659.20K
TURNOVER
--
52 WEEK HIGH
19.87
52 WEEK LOW
4.190
MARKET CAP
1.23B
P/E (TTM)
-13.6523
1D
5D
1M
3M
1Y
5Y
1D
Silence Therapeutics GAAP EPS of -$0.08 beats by $0.05
Seeking Alpha · 12h ago
Silence Therapeutics GAAP EPS of -$0.08
Seeking Alpha · 12h ago
Silence Therapeutics Q3 EPS $(0.24) Misses $(0.12) Estimate
Benzinga · 12h ago
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Barchart · 19h ago
J&J gets into psychedelic treatments with backing of Delix Therapeutics
Seeking Alpha · 3d ago
Weekly Report: what happened at SLN last week (1102-1106)?
Weekly Report · 3d ago
Weekly Report: what happened at SLN last week (1026-1030)?
Weekly Report · 11/02 10:25
Weekly Report: what happened at SLN last week (1019-1023)?
Weekly Report · 10/26 10:25
More
About SLN
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Webull offers Silence Therapeutics PLC - ADR stock information, including NASDAQ: SLN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLN stock methods without spending real money on the virtual paper trading platform.